5-(2-Chloroethyl)-4-Methylthiazole

4-Methyl-5-thiazoleethanol (CAS 137-00-8), the workhorse roast-nut and meaty note in process flavors, is manufactured at production scale via alkaline hydrolysis of 5-(2-chloroethyl)-4-methylthiazole. The batch reaction is carried out in a 5,000 L glass-lined reactor equipped with a dual-tier pitched-blade agitator operating at 85–90 °C under a nitrogen blanket. Aqueous sodium hydroxide (50% w/w) is metered to a final molar ratio of 1.02–1.10 eq. relative to the chlorothiazole feed, with addition of 0.15–0.30 mol% tetrabutylammonium bromide as phase-transfer catalyst to suppress interfacial mass transfer resistance. After 4–6 h reaction time, the organic phase is separated, neutralized with phosphoric acid to pH 7.0 ± 0.2, and vacuum-distilled over a packed column to yield sulfurol with purity >99.5% (GC-FID). In-process controls follow FEMA 3204 and JECFA 1160 specifications; the finished aroma chemical must comply with EU Regulation 1334/2008/EC and carry a 2-chloroethanol residue below 2 mg/kg, verified by EN 1528-1 extraction and GC-MS quantification. The isolated sulfurol is subsequently blended into compounded savory flavors at usage levels between 0.5 mg/kg and 50 mg/kg in final food products, delivering roast, cocoa, and meat character in retorted soups, snack seasonings, and plant-based meat analogues. Failures linked to acidic runaway—where prolonged heating at pH <9 led to thiazole ring scission and formation of ammonia-laden off-notes—have been documented when the caustic metering line stalls, a scenario mitigated by redundant pH probes and a torque-based agitator interlock that halts steam supply on viscosity spikes.

Can Direct Hydrolysis of the Chloroethyl Arm Secure an ICH M7-Compliant Thiamine Thiazole Feedstock?

In the thiamine (vitamin B1) supply chain, 5-(2-chloroethyl)-4-methylthiazole serves as the entry point to the thiazole moiety 4-methyl-5-(2-hydroxyethyl)thiazole after nucleophilic substitution with formate salts or hydroxide. The conversion is integrated into a multi-step synthesis aligned with European Pharmacopoeia (Ph. Eur.) monograph 0303 and USP <231> residual solvent guidance; the primary regulatory burden revolves around mutagenic impurity classification under ICH M7, where chloroethanol and residual chloroethyl precursor must be controlled below the threshold of toxicological concern (TTC) of 1.5 µg/day. A typical charge in a 2,000 L Hastelloy C-22 reactor combines 350 kg 5-(2-chloroethyl)-4-methylthiazole with 210 kg calcium formate and 400 L deionized water, held at 102–105 °C for 8–10 h with continuous removal of chloroform vapor. The crude hydroxyethyl intermediate is extracted into dichloromethane, dried over molecular sieves, and purified via fractional distillation under 2–3 mbar vacuum, achieving a purity suitable for condensation with a phosphorylated pyrimidine partner. The final API, thiamine hydrochloride or thiamine mononitrate, is crystallized from ethanol and must pass Ph. Eur. 2.3.3 for chloride limits. Process capability studies on twin-cone vacuum dryers (3,000 L capacity) have shown that residual moisture exceeding 0.3% in the thiazole intermediate prior to the coupling step reduces yield by 8–12% and elevates the dimeric byproduct. The addition ratio of the chloroethyl feedstock to the pyrimidine component, based on published process patent data, is typically adjusted to 1.03:1 to compensate for minor handling losses in the preceding hydrolysis step.

Integration of the 4-methylthiazole moiety into peptidomimetic HIV-1 protease inhibitors routinely exploits the alkylating functionality of 5-(2-chloroethyl)-4-methylthiazole. In a validated GMP step under ICH Q7 and FDA 21 CFR Part 211, the compound is reacted with a deprotonated secondary amine intermediate—typically a substituted (R)-hydroxyethylamine—in anhydrous dimethylformamide containing 1.2 eq. potassium carbonate and 0.05 eq. potassium iodide. The batch is charged into a glass-lined reactor (1,000–2,500 L) maintained under a dry nitrogen purge (dew point ≤ -40 °C) and heated to 55–60 °C with slow-motion agitation (120–150 rpm) for 12–16 h. Reaction completion is verified by HPLC with UV detection at 254 nm; endpoint specification allows ≤ 1.0 area% residual starting amine. After aqueous work-up and silica gel plug filtration, the coupled intermediate is precipitated from n-heptane/isopropanol to yield a crystalline solid. Residual solvent analysis against ICH Q3C limits requires DMF ≤ 880 ppm and tetrahydrofuran ≤ 720 ppm, executed on a headspace GC-FID system calibrated with Class 2 solvent mixtures. The resultant thiazole-appended intermediate is ultimately converted to a protease inhibitor active pharmaceutical ingredient, such as a generic darunavir or atazanavir synthon, for combination antiretroviral therapy. Production-scale deviations have been traced to moisture ingress through mechanical seal leaks, causing premature hydrolysis of the 2-chloroethyl group and formation of the corresponding alcohol impurity that co-elutes with the product under standard TLC conditions; in-line Karl Fischer titration monitoring with pre-set alarm at 0.08% water in the reaction matrix has been implemented as a corrective action. The validated process achieves a mean yield of 78–82% after crystallization and meets EMA guidelines for mutagenic impurity control of the chloroethyl starting material, which is limited to ≤ 10 ppm in the final drug substance.

Thifluzamide Backbone Construction – Oxidative Disconnection of the Chloroethyl Chain

The conversion of 5-(2-chloroethyl)-4-methylthiazole into 4-methylthiazole-5-carboxylic acid, the central building block of the carboxamide fungicide thifluzamide, proceeds via a potassium permanganate oxidation protocol that has been scaled to multi-ton batches in agrochemical contract manufacturing. The synthesis is conducted under FAO Specification 97/TC/TK quality requirements for technical-grade active ingredient and must comply with OECD Test Guideline 301B for ready biodegradability of process effluents. In a 6,300 L glass-lined oxidizer, the chlorothiazole is suspended in water and treated with 2.2–2.5 eq. KMnO₄ in portions, maintaining the internal temperature at 30–35 °C with jacket cooling; a sharp exotherm beyond 42 °C initiates runaway manganese dioxide precipitation and potential radical side reactions that reduce the acid titre by 15–20%. After the oxidation is complete, manganese dioxide slurry is removed via a plate-and-frame filter press, the mother liquor is acidified to pH 2.0 with 32% hydrochloric acid, and crude carboxylic acid is precipitated, centrifuged, and washed with cold water to remove chlorides. Drying in a fluid-bed dryer at 60 °C to residual moisture <0.5% yields a tan solid with purity ≥98.5% (HPLC, 210 nm). This acid is then coupled with 2',6'-dibromo-4'-(trifluoromethoxy)aniline using thionyl chloride activation to form thifluzamide technical, which is formulated as a 23% SC suspension concentrate or 50% WDG water-dispersible granule. The molar feeding ratio of chloroethyl raw material to the substituted aniline in the overall production campaign is calculated at 1.00:0.92 to offset the 6–8% mechanical losses across the oxidation and chlorination steps. Residue analysis must confirm free 2-chloroethanol is absent (LOD 0.1 mg/L) in the final formulated product, verified by CIPAC MT 170 LC-MS/MS, to satisfy EU MRL filing. The downstream production process highlights the need for secondary containment for permanganate slurry handling and stringent temperature cascade limits.

Within medicinal chemistry campaigns targeting histone deacetylases (HDACs) for oncology indications, the 4-methylthiazole nucleus offers a favorable zinc-chelating pharmacophore isostere; 5-(2-chloroethyl)-4-methylthiazole is elaborated into a library of N-substituted thiazole acrylamides in a continuous-flow microreactor platform. The process, governed by early-phase ICH S9 guidance for non-clinical safety evaluations and GLP-compliant impurity profiling, begins with the quaternization of the thiazole nitrogen using methyl triflate, followed by displacement of the chloroethyl arm with aniline derivatives under 3.0 bar back-pressure in a PEEK microreactor at 120 °C. Molar input ratios of thiazole to aniline derivative are precisely maintained at 1:1.05 using syringe pumps; total residence time is 12 min. The output stream is quenched with 1 M sodium bicarbonate and extracted into ethyl acetate. The critical quality attribute is the minimization of the ring-opened byproduct that appears when water content in the reagent line exceeds 0.2%, causing a pH shift and heterocycle cleavage. The resulting acrylamide intermediates are further transformed into hydroxamic acid final products—candidacy HDAC inhibitors—with inhibitory IC50 values typically in the low nanomolar range. Though published toxicological data for this specific class remain limited, the presence of the chloroethyl precursor mandates a control strategy that ensures alkylating potential screening via AMES (OECD 471) assay with a result negative at ≤ 5,000 µg/plate. The terminal article is an investigational antitumour API, dosed in Phase I clinical trials, and the CMC package references ICH Q11 for development and manufacture of the drug substance.